Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2017-004542-24Phase 4Unknown
Phase 4, randomised, open-label trial of methotrexate, 5-aminosalicylic acid + sulphasalazine, leflunomide and adalimumab in psoriatic arthritis (PsA) (3 arms), sponsored by University of Oxford. Primary endpoint: PASDAS good response at week 24. Status: unknown.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2017-004542-24.